search

Active clinical trials for "Purpura, Thrombocytopenic, Idiopathic"

Results 311-320 of 380

Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study

Primary Immune Thrombocytopenia

Description of the use of fostamatinib in patients with PTI in the Andalusian region.

Completed7 enrollment criteria

Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy...

Immune ThrombocytopeniaThrombopoietin Receptor Agonist

TPO-r Switch is a retrospective study of the patients affected by Immune Thrombopenia (ITP) who received alternatively romiplostim and eltrombopag.

Completed6 enrollment criteria

Study of Immune Thrombocytopenia Pathogenesis:

Primary Immune Thrombocytopenia (ITP)

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet count responsible for bleedings. The disease is mostly mediated by antiplatelet antibodies produced by specific B cells. However, T cells are also involved but their role is not completely understood. The aim of this study is to determine the implication of T cells in the pathogenesis of ITP, notably regulatory T cells (Treg, CD4+CD25highFoxp3+), cytotoxic T cells (CD3+CD8+) and T follicular helper cells (TFH, CD3+CD4+CXCR5+PD-1+ICOS+), in blood and in the spleen of primary ITP patients, compared to healthy controls.

Completed7 enrollment criteria

TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.

Adult PatientsImmune Primary Thrombocytopenia2 more

This study aims at analyzing the therapeutic activity of TPO-mimetics Eltrombopag and Romiplostim as bridge therapy for splenectomy in adult patients with primary immune thrombocytopenia.

Completed6 enrollment criteria

Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune...

Immune Thrombocytopenic Purpura

The purpose of this study is to determine whether All-trans retinoic acid (ATRA) are effective in the treatment of refractory idiopathic thrombocytopenic purpura (RITP).

Completed3 enrollment criteria

Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura

Idiopathic Thrombocytopenic PurpuraImmune Thrombocytopenic Purpura

The purpose of this study is to determine how children with a history of severe, chronic Idiopathic Thrombocytopenic Purpura (ITP) who were treated with rituximab might respond to vaccines. Eligible patients are previously or currently enrolled in a study entitled "Open Label, Phase I/II Trial of Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura in Children and Adolescents" and have decided to obtain an inactivated influenza vaccination. These patients will be invited to provide one blood sample prior to vaccination and a second sample following vaccination to quantify immune response to vaccination.

Completed5 enrollment criteria

Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics

Immune Thrombocytopenia

Introduction: Ineffective platelet production has been proven to play a role in the etiology of Immune Thrombocytopenia (ITP) in addition to increased platelet destruction. The second-generation thrombopoietin (TPO) mimetics have shown good efficacy in boosting platelet counts in the great majority of patients with chronic ITP in several clinical trials.1, 2 Nevertheless, about 20% of patients with ITP fail to respond to the TPO mimetic treatment. Those treatment-resistant patients are un-characterized and the reasons for the lack of response have not been studied. The identification of predictive blood biomarkers of patients' response to treatment will be useful in reducing both cost and potential side effects; and it will be of equal importance and interest to investigate the molecular mechanisms underlying the patients' heterogeneous responses to TPO mimetic treatment. Specific Aims: To identify blood classifier genes which correlate with patients' response to TPO mimetic treatment. To compare the blood gene expression changes in responders and non-responders after TPO mimetic treatment and explore the possible molecular mechanisms accounting for the non-responsiveness to the treatment.

Completed2 enrollment criteria

Promacta Pregnancy Registry

PurpuraThrombocytopaenic1 more

Since Idiopathic Thrombocytopenic Purpura (ITP) affects women who are of reproductive capacity and taking into account the lack of data concerning Eltrombopag (Promacta) use during pregnancy, the Eltrombopag (Promacta) Registry will be an essential component of the ongoing risk management for Eltrombopag (Promacta). The Registry will detect and record the events (live births, spontaneous abortions, stillbirths, elective terminations, therapeutic terminations, any serious pregnancy outcome, major and minor congenital anomalies, outcomes including preterm, small for gestation age, or intrauterine growth restriction adverse adverse effects on the following: immune system development, platelet number and function, neoplasm formation, bone marrow reticulin formation, thrombotic events) in the mother and/or the neonate/infant. The adverse events in the infant will be assessed through at least the first year of life. The Pregnancy Registry will compare the pregnancy and fetal outcomes of women exposed to eltrombopag Tablets during pregnancy to an unexposed control population. This study will be a prospective observational, exposure follow-up study.

Completed1 enrollment criteria

Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"

Gastric/Duodenal UlcerGastric MALT Lymphoma3 more

The purpose of this study is to evaluate the safety and efficacy on participants receiving first-line eradication and second-line eradication including vonoprazan (Takecab) tablets (triple therapy) in the routine clinical setting.

Completed4 enrollment criteria

Drug Use Investigation for REVOLADE (ITP)

PurpuraThrombocytopaenic1 more

To investigate safety and efficacy in the actual use of REVOLADE collected from all subjects receiving the drug until data from a specified number of subjects are accumulated to identify factors considered to influence its safety and efficacy. <Priority investigation item> Thromboembolism

Completed2 enrollment criteria
1...313233...38

Need Help? Contact our team!


We'll reach out to this number within 24 hrs